[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immunome Inc (IMNM)

Immunome Inc (IMNM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Can Immunome's Varegacestat Data Justify What Investors Are Now Willing to Overlook?

Immunome Inc (NASDAQ: IMNM) reports first-quarter 2026 earnings on May 11, 2026, with analysts expecting a loss of $0.60 per share. The biotechnology company faces a critical test as investors assess whether its clinical pipeline can justify a valuation that has climbed 25% above its 200-day moving average despite persistent losses. With 14 of 15 analysts rating the stock a Strong Buy and a consensus price target implying 58% upside, the question is whether IMNM can demonstrate progress that validates the Street's bullish conviction.

Immunome is a clinical-stage biotechnology company developing targeted therapies for oncology and infectious diseases, leveraging its proprietary antibody discovery platform to identify novel therapeutic...

Fundamentals

See More
  • Market Capitalization, $K 2,541,330
  • Shares Outstanding, K 113,250
  • Annual Sales, $ 6,940 K
  • Annual Income, $ -212,390 K
  • EBIT $ -234 M
  • EBITDA $ -234 M
  • 60-Month Beta 2.11
  • Price/Sales 362.05
  • Price/Cash Flow N/A
  • Price/Book 3.86

Options Overview Details

View History
  • Implied Volatility 70.51% (+4.24%)
  • Historical Volatility 53.33%
  • IV Percentile 2%
  • IV Rank 1.82%
  • IV High 298.95% on 09/19/25
  • IV Low 66.28% on 05/07/26
  • Expected Move (DTE 4) 0.37 (1.67%)
  • Put/Call Vol Ratio 2.00
  • Today's Volume 18
  • Volume Avg (30-Day) 102
  • Put/Call OI Ratio 0.63
  • Today's Open Interest 6,164
  • Open Int (30-Day) 6,492
  • Expected Range 22.07 to 22.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.60
  • Number of Estimates 7
  • High Estimate $-0.53
  • Low Estimate $-0.66
  • Prior Year $-0.52
  • Growth Rate Est. (year over year) -15.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.42 +4.76%
on 04/09/26
24.90 -9.88%
on 04/20/26
+0.74 (+3.41%)
since 04/08/26
3-Month
19.16 +17.12%
on 03/30/26
25.21 -10.99%
on 02/11/26
-2.44 (-9.81%)
since 02/06/26
52-Week
7.39 +203.65%
on 05/09/25
27.65 -18.84%
on 02/04/26
+14.73 (+191.05%)
since 05/08/25

Most Recent Stories

More News
Can Immunome's Varegacestat Data Justify What Investors Are Now Willing to Overlook?

Barchart Research What to Expect from IMNM Earnings IMNM Generated May 8, 2026 Current Price $22.44 EPS Estimate $$-0.60 Consensus Rating Strong Buy Average Move 3.95% Can Immunome's Varegacestat Data...

IMNM : 22.44 (+1.13%)
Can Immunome's Varegacestat Data Justify What Investors Are Now Willing to Overlook?

Barchart Research What to Expect from IMNM Earnings IMNM Generated May 8, 2026 Current Price $22.44 EPS Estimate $$-0.60 Consensus Rating Strong Buy Average Move 3.95% Can Immunome's Varegacestat Data...

IMNM : 22.44 (+1.13%)
Can Immunome's Varegacestat Data Justify What Investors Are Now Willing to Overlook?

Barchart Research What to Expect from IMNM Earnings IMNM Generated May 8, 2026 Current Price $22.44 EPS Estimate $$-0.60 Consensus Rating Strong Buy Average Move 3.95% Can Immunome's Varegacestat Data...

IMNM : 22.44 (+1.13%)
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on May 1, 2026, the Compensation...

IMNM : 22.44 (+1.13%)
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors

New Drug Application (NDA) supported by positive Phase 3 RINGSIDE results, including significant improvement in progression-free survival vs. placebo (hazard ratio = 0.16, p

IMNM : 22.44 (+1.13%)
Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting

Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that data from RINGSIDE, its...

IMNM : 22.44 (+1.13%)
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on April 1, 2026, the Compensation...

IMNM : 22.44 (+1.13%)
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on March 2, 2026, the Compensation...

IMNM : 22.44 (+1.13%)
Immunome Reports Full Year 2025 Financial Results and Provides Business Update

New Drug Application submission for varegacestat in patients with desmoid tumors planned for 2Q 2026 IM-1021 Phase 1 ongoing with initial data expected in 2026 Three...

IMNM : 22.44 (+1.13%)
Immunome to Present at Upcoming Investor Conferences

Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome’s management...

IMNM : 22.44 (+1.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Immunome, Inc. is a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Immunome, Inc. is based in Exton, United States.

See More

Key Turning Points

3rd Resistance Point 23.40
2nd Resistance Point 23.05
1st Resistance Point 22.75
Last Price 22.44
1st Support Level 22.09
2nd Support Level 21.74
3rd Support Level 21.44

See More

52-Week High 27.65
Last Price 22.44
Fibonacci 61.8% 19.91
Fibonacci 50% 17.52
Fibonacci 38.2% 15.13
52-Week Low 7.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.